Direct democracy Switzerland: How To
Your browser is out of date. It has known security flaws and may not display all features of this websites. Learn how to update your browser[Close]

Contraceptive case

Health fund seeks compensation from pill maker

The pill is a popular means of birth control (Keystone)

The pill is a popular means of birth control


Complications attributed to the use of the Yasmin contraceptive pill have prompted a Swiss health insurance company to demand hundreds of thousands of francs from the German pharma giant, Bayer, to pay for a client’s treatment.

The claim arose after a young woman suffered a pulmonary embolism after taking the pill, leaving her severely handicapped. Her family has already launched a legal case against Bayer on their own account. Their lawyer told Swiss television on Tuesday that the CSS insurance company had now made a so-called “third party intervention” in her support.

He said CSS had so far paid out SFr600,000 ($650,000) for her treatment, and more than SFr900,000 in another case.

“It is not right that the community should pay while the Bayer company makes a profit,” he said.

Until 2010 Yasmin, a “fourth generation” pill, was the best-selling hormonal contraceptive in Switzerland. Fourth generation pills were popular because women using them did not put on as much weight as with earlier pills.

In 2009 Swissmedic, the agency that supervises therapeutical products, found that it did present a higher risk of thrombosis than second generation pills, but was safer than pills of the third generation. But it stressed that women should only use hormonal methods after consulting their doctor.

Just before Swissmedic announced its findings, a woman died of a pulmonary embolism ten months after she started taking Bayer’s Yaz contraceptive, the lower dose version of Yasmin. and agencies


It is only permitted to use a hyperlink to specific SWI content on the website of the party requesting the content or the website of a third party. The framing of content from SWI is only allowed if it is unchanged, without advertising.

Articles can be copied and used if these guidelines are followed:

The article can only be used if it clearly mentions “[author],” For any further use, please send an email to: The editorial content on SWI adheres to the guidelines, rights and duties specified by the Swiss Press Council. If content not adhering to those outlined by the Press Council are found on third-party website displaying SWI content, SWI can demand that all SWI content be removed from the corresponding pages.